Income before deduction of interest, taxes and amortization: morphosys.com (MOR)
The determination of MorphoSys AG management to focus on its key oncology drug and the advantageous merger with Novartis are evident when monitoring operating profit in monetary terms on the GURU.Markets chart, where the current parameter equals . The business is minimizing Capex, generating revenue through royalties from global partners. The team is currently adapting to new structures while maintaining a high level of confidence in its programs.
Summary analytical data breakdowns for MorphoSys (MOR)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- book capitalization information:
- business debt structure and liquidity details:
- earnings and market multiples details:
MOR - Company Net Income|Company Profit Forecast MorphoSys AG|MOR - Price to Earnings Ratio|Projected Price to Earnings Ratio morphosys.com|MOR - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio MorphoSys|MOR - Operating profit before deduction of amortization|Earnings per share for the trailing year MorphoSys|MOR - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth morphosys.com|MOR - Earnings growth in current year|Net earnings per one share growth forecast for next year MorphoSys AG
Analysis of all company metrics:MorphoSys Corporation, MOR
Integrating ESG standards into the development of oncology drugs at MorphoSys AG (MOR) requires significant expenditures on environmental safety and research ethics. Absolute EBITDA captures the actual cash flow from core operations before depreciation and taxes, allowing for the separation of temporary market fluctuations from fundamental business stability. Analyzing absolute EBITDA trends helps investors identify hidden opportunities while ignoring short-term liquidity noise.
Who MorphoSys AG competes with
Operating profit EBITDA BeiGene Oncology ONC|HALO - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization RVMD (revmed.com)|AAPG: Operating profit EBITDA|Profit before interest, taxes and amortization CG Oncology Inc (CGON)|Profit before payment of interest, taxes and amortization UroGen|Operating profit before deduction of amortization Bicara Corp (BCAX)|Profit before payment of interest, taxes and amortization Personalis, Inc. (PSNL)|ERAS - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Delcath Systems DCTH|Income before deduction of interest, taxes and amortization YMAB|AURA - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization CADL|ARAY: Operating profit EBITDA|SELLAS Life Sciences Group - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Actuate Therapeutics|Profit before interest, taxes and amortization Citius Oncology Inc. CTOR|Profit before payment of interest, taxes and amortization TuHURA Biosciences, Inc. (HURA)|Operating income before deduction of amortization Protara Tx|Fate Therapeutics, Inc. - Operating profit before deduction of amortization|Aadi Bioscience, Inc. (WHWK) - Profit before interest, taxes and amortization|TCRX - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Champions Oncology CSBR|XBIT (xbiotech.com) - Operating profit before deduction of amortization|CEL-SCI - Income before deduction of interest, taxes and amortization|OSTX (OS Therapies Incorporated) - Operating profit EBITDA|Operating profit EBITDA radiopharmtheranostics.com|Operating profit EBITDA ARTV|adlainortye.com (ANL) - Operating profit before depreciation charges|Profit before payment of interest, taxes and amortization Veru Pharma VERU|TPST - Operating profit before deduction of amortization|XLO - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Renovaro Inc.|muraloncology.com (MURA) - Profit before payment of interest, taxes and amortization|Kairos Pharma - Income before deduction of interest, taxes and amortization|OKUR (OnKure Therapeutics, Inc.) - Operating profit EBITDA|Operating profit before deduction of amortization CytoMed (GDTC)|Operating profit EBITDA CRIS|Operating profit EBITDA apollomicsinc.com (APLM)|Profit before payment of interest, taxes and amortization Tharimmune THAR|ADVB: Operating profit before amortization|Genprex, Inc - Operating profit EBITDA|Calidi Biotherapeutics (CLDI) - Operating profit before deduction of amortization|SBFM: Operating profit EBITDA|Profit before interest, taxes and amortization Xenetic Biosciences, Inc. (XBIO)|Profit before payment of interest, taxes and amortization Salarius Pharmaceuticals, Inc.|PPBT: Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization AONC (American Oncology Network)|BGNE (BeiGene Ltd) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA CKPT (Checkpoint Therapeutics)|ELEV - Operating profit before deduction of amortization|ICAD: Operating profit before deduction of amortization|IKNA - Operating profit EBITDA|Notable Labs Inc. (NTBL) - Profit before payment of interest, taxes and amortization|Viracta Therapeutics, Inc. - Income before deduction of interest, taxes and amortization|NAYA (NAYA Biosciences) - Operating profit EBITDA|Profit before interest, taxes and amortization ascentage.com AAPGV
